Q3 FY25 Trading Update
| Stock | Beamtree Holdings Ltd (BMT.ASX) |
|---|---|
| Release Time | 6 May 2025, 8:21 a.m. |
| Price Sensitive | Yes |
Beamtree Reports Strong Q3 FY25 Trading Update
- Major contract wins including Evolve Collaborative with NHS Confederation and autonomous coding product expansions
- Targeting 20% annual recurring revenue growth for FY25 with improved profitability
- Strong pipeline of opportunities across all markets and products supporting accelerated growth
Beamtree Holdings Limited (ASX: BMT), a leading provider of AI decision support and data insights solutions for the healthcare sector, has released a trading and operational update for the third quarter to 31 March 2025 (Q3 FY25) of the current financial year to 30 June 2025 (FY25). The company has made significant progress across its business, securing major contract wins including the launch of the Evolve Collaborative with the NHS Confederation in England, the development of its autonomous coding product with contracts across Australia, the UK, and Canada, and the renewal of its contract with the Healthcare Pricing Office in the Republic of Ireland. Beamtree continues to target the delivery of annual recurring revenue (ARR) growth of over 20% for FY25, with improved profitability in the second half of FY25 and achieving positive cash generation by the end of FY25. The company remains confident in delivering ARR of $30 million going into the next financial year, with a strong pipeline of opportunities across all its markets and products supporting accelerated growth. Cost management remains a focus, with operating cost growth expected to be below revenue growth to deliver improved profitability in FY25.
Beamtree expects to deliver annual recurring revenue (ARR) of $30 million going into the next financial year (FY26), with a strong pipeline supporting further growth towards the stated target of $60 million ARR by the end of 2026.
Beamtree continues to have a strong pipeline of opportunities across all its markets and products, with this pipeline maturing and supporting the expected acceleration in recurring revenue growth towards the end of FY25 and in the next financial year. The company reaffirms expected annual recurring revenue growth of over 20% for FY25 and further upside looking into 1H FY26 and in 2026.